ClinicalTrials.gg
RecruitingNCT07066033PSYNIGEDUpdated Aug 18, 2026

A Study of the Intestinal Microbiota in Children and Adolescents With Eating Disorders. A Perspective From Psychoneuroimmunology

An observational study in Eating Disorders in Adolescence and Eating Disorders in Children, sponsored by Esther Nova. Recruiting at 2 sites in Spain. Open to participants aged 7 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Esther Nova · Observational

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
158
Ages
7 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Feeding and Eating Disorders with a site in Spain — 10 open to participants now, 11 under way, none of them phase 3. Feeding and Eating Disorders · Spain.

Started
2024
with 2 others
Observational
5 of 28
2 open now
Primary completion
2026-12
later than 5 of 10 live
Registered
20th of 28
by date
Lead sponsor
1 of 28
Esther Nova

Among the 28 studies in Feeding and Eating Disorders with a site in Spain, this one is one of 3 that started in 2024, is one of 5 observational ones, reaches primary completion later than 5 of the 10 other live ones, and was the 20th registered.

Feeding and Eating Disorders

645 studies on the registry are indexed under Feeding and Eating Disorders; 151 are open to participants now.

Browse Feeding and Eating Disorders studies →

Open to participants now

10 of the 28 studies in Feeding and Eating Disorders with a site in Spain are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 99 Feeding and Eating Disorders studies recruiting now, 31 (31%) set no upper age limit and 66 (67%) stop at 75 or younger; 45 take children under 18; 20 take healthy volunteers.

This study: 7 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Feeding and Eating Disorders with a site in Spain, or all of them as a file.
02

Study summary

The goal of this observational study is to learn if behavioral and psychological factors are associated with the intestinal microbiota composition and function in children and adolescents with eating disorders (ED). The main questions it aims to answer are:

  • Are there any differences between the microbiota composition and function in adolescent patients with eating disorders and healthy adolescents?
  • Are the dietary pattern and other lifestyle habits associated with the intestinal microbiota composition in patients with a recent onset eating disorder?
  • Is it possible to predict the treatment response at one year by looking at any of the psychological and biological factors measured in the patients at baseline?
  • Are there any differences in the intestinal microbiota among patients with different subtypes of anorexia nervosa (restrictive, binge-purging, atypical) or with avoidance/restrictive food intake disorder (ARFID)? Researchers will compare the results with those obtained from a group of healthy children and adolescents matched by sex and age to find out if the associations observed differ between ED and control participants.

Participants with ED will fill in different lifestyle questionnaires and psychological tests; they will also undergo anthropometrical measurements and will provide fecal and blood samples at baseline and one year later. Healthy participants will provide the same lifestyle information, anthopometrical measurements and stool and blood samples. They will only undergo the baseline evaluation.

Read the detailed description

BACKGROUND: Eating disorders (ED) are severe and complex psychiatric pathologies characterised by the presence of abnormal eating patterns. There is not an easy cure, the clinical courses are long and often present medical, psychiatric and family complications that influence their evolution and prognosis. Almost half of the patients continue with symptoms many years after their first episode. So far, the etiology of AN remains unclear but it certainly seems to encompass multiple intertwined genetic and environmental factors, that seem to affect appetite, behavioral pathways, psychological traits and hypothalamic-pituitary-adrenal (HPA) axis dysregulation. Socio-cultural and familiar factors may favor the onset of an ED. More specifically, there are hypotheses involving brain neurotransmitters and dysregulation of reward systems, via pathways in which the gut-brain axis may be involved. The gut microbiota synthesizes or regulates the production of short-chain fatty acids (SCFAs), bile acids, tryptophan metabolites, and various neurotransmitters and hormones that may affect the central nervous system.

AIM: the study investigates whether the composition and function of the intestinal microbiota in children and adolescents with eating disorders are different from those of healthy children and adolescents. Secondarily, the relationship between the dietary pattern prior to enrollment, the psychopathology symptoms and the intestinal microbiota will be assessed.

STUDY DESIGN: a cross-sectional controlled study will be performed where the microbiota of children and adolescents with ED (AN any subtype or ARFID) will be compared with that of healthy participants matched by sex and age.

SUBJECTS: All patients referred to the specialized ED unit of the Hospital Infantil Universitario Niño Jesús that fulfill inclusion and exclusion criteria and who are willing to participate will be included. Diagnosis will be performed by psychiatrists with DSM-5 criteria.

The following information will be gathered during the interview: i) developmental history, ii) medical and psychiatric history, iii) Behaviors around the ED, iv) psychopharmacological treatment, v) sleep quality and quantity.

Healthy children and adolescents matched by sex and age will be included used as control group, who will be enrolled at their education centers.

BIOMARKER ANALYSES:

  1. anthropometry and body composition study (BMI Z-score, arm circumference and tricipital skinfold thickness, bioimpedance analysis)
  2. blood biomarkers: hematology, routine biochemistry, insulin, cortisol, T3; Leptin, active Ghrelin, Total PYY, active GLP-1, adiponectin, plasma inflammatory cytokines, intestinal permeability mediators of inflammation and neurotransmitters.
  3. fecal biomarkers: intestinal microbiota composition analysis using shot-gun metagenomic and deep sequencing and functional genetic mechanisms; neurotransmitters (HPLC), short-chain fatty acids.

PSYCHOMETRIC TESTS: aiming the assessment of i) ED specific psychopathology (EDI-II) ii) comorbidities (anxiety and depression), iii) personality, iv) stressful life events. The family will also fill in i) ED symptoms, ii) care giver experience, iii) parental functioning.

DIETARY STUDY: includes i) 24-hour recall, ii) food frequency questionnaire over the last 15 days and iii) questionnaire on dietary habits. Dietary patterns and diet quality indexes will be derived.

STOOL PROCESSING: Stool samples, at least the size of a walnut are stored at -80C until different aliquots are separated and weighed into processing tubes for the different techniques. For fecal microbiota composition analysis specimens are analyzed as follows: bacterial DNA extraction with chromatographic column and a prior optimization step, shot-gun Illumina DNA sequencing, generation of Operational Taxonomic Unit (OTU) tables at different taxonomic levels, functional gene annotation. The DNA purification is done at the Institute of Food Science, Technology and Nutrition, CSIC and the shot-gun sequencing and bioinformatic analysis at the Microbiological Unit of the Hospital Ramón y Cajal, Madrid, Spain.

SAMPLE SIZE: previous data on microbiota in the pediatric population with ED are lacking as well as those of healthy children from the reference population. The sample size calculation performed was based on an expected effect of moderate-large size according to published findings comparing AN patients and healthy women microbiota and SCFA. For the current study to prove a medium effect size (d=0.45) in the microbiota variables with a confidence level 95% and power 80%, the result was 79 subjects per group. The ex-post power of the differences observed will be calculated.

STATISTICAL METHODS: To identify significant and predictive factors among psychological, clinical and biological variables studied, multivariate predictive models will be run on the different outcomes: binary and multidimensional. The predictive models will be chosen according to the statistical restrictions of the data.

ONE YEAR FOLLOW UP ASSESSMENT: one year after entering the study, participating patients, only, will be evaluated with the same procedures as in the baseline study to check the differences in microbiota composition with time and study potentially prognostic factors.

ETHICS: The study is approved by the Research Ethics Committee at the Hospital Infantil Universitario Niño Jesús (reference number: 0068/23. 28 November 2023) and the Ethics Committee at the Spanish National Research Council (CSIC) (reference number: 245/2023. 22 January 2024). All sensitive information of personal or biological origin will be treated with confidentiality and according to the Spanish law. All biological specimens will be treated according to specified storage, reutilization and discarding procedures as consented by the participating subjects or their legal representatives.

PERSPECTIVES: The results and findings derived from this study will help understand whether the intestinal microbiota contributes to AN etiopathology and might provide evidence to support treatment strategies for personalized treatments and better disease prognosis.

03

Conditions studied

  • Eating Disorders in Adolescence
  • Eating Disorders in Children

Keywords

  • Eating disorders
  • psychopathology
  • intestinal microbiota
  • diettary pattern
  • neuroendocrine peptides
  • neurotransmitters
  • inflammation
  • short chain fatty acids
  • metagenomics
  • prognostic factors
04

Who can participate

Ages eligible
7 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All patients will be recruited in the ED specialized unit of the Niño Jesus University Children Hospital (NJUCH) after receiving a DSM-V ED diagnosis by an experienced psychiatrist. Patients will be eligible on treatment modalities including hospitalization, outpatient consultations or home hospitalization.

The control group will be recruited among healthy children and adolescents attending eligible levels in private and public centers of formal education. Eligible educational centers are those located in geographical areas included in the administrative health zones assigned to the NJUCH. A combination of private and public schools from both metropolitan and peripheral cities is being selected. Invitation letters are sent to the head of the schools and following acceptance, randomization of age levels across schools is performed.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 7-17.9 years
  • Diagnosis of Anorexia Nervosa, both restrictive (ANR) and binge-purging (ANBP) subtypes, Other Specified Feeding and Eating Disorders (OSFED), Avoidant/Restrictive Food Intake Disorder (ARFID) according to (APA, 2013).
  • Males and females
  • First episode or less than 1 year evolution since initial symptoms
  • Written by parent/tutor and also by the adolescent if age is more than 12 y.

Exclusion criteria

Exclusion Criteria:

  • Comorbidities: Current infectious disease at admission; Severe neurodevelopmental disorders with impaired language development; Moderate or severe intellectual disability; Endocrine disorders such as diabetes mellitus or thyroid disease; Celiac disease; Suicidal behaviors in the previous 3 months.
  • Patients with previous unsuccessful treatments for more than one year.
  • Use of the following medications before entering the study: laxatives, anabolic steroids, drugs, Helicobacter pylori eradication treatment, thyroid hormones or antibiotic treatment in the previous two months
  • Surgery in the previous month. Control group participants' exclusion criteria are the same plus the following: History with diagnosis of mental disease (including EDs). Current or infectious disease.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
158 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Eating disorder patients

    Children and adolescents with a recent onset eating disorder initiating treatment in a Specialized Eating Disorder Unit

  • Control group

    Healthy children and adolescents matched by age and sex with the ED patients

06

What researchers measure

Primary outcomes

  1. Intestinal microbiota composition

    Intestinal microbiota composition as derived from Shot-gun metagenomics with deep-sequencing analysis will be used on stool isolated DNA.

    Time frame: Baseline

  2. Intestinal microbiota function

    Microbial metabolites will be analyzed in fecal water, including SCFA by gas chromatography-FID and aminoacids and neurotransmitters (GABA, dopamine, serotonin) by HPLC.

    Time frame: Baseline

Secondary outcomes

  1. Hematology

    White blood cells (WBC) and differential.

    Time frame: baseline

  2. Routine biochemistry

    Glucose, hepatic enzymes (GOT, GPT, gamma-GT), urea, creatinine, uric acid, total bilirubin; C-reactive protein, lipid profile (Cholesterol, HDL-cho, LDL-cho, VLDL-cho).

    Time frame: Baseline

  3. Hormones, gastrointestinal and adipose tissue peptides

    Insulin, Cortisol, Leptin, active Ghrelin, Total PYY, active GLP-1; and Adiponectin.

    Time frame: Baseline

  4. Systemic Inflammation

    plasma inflammatory cytokines (MCP-1, IL-2; IL-1beta, IL-6, TNF-alfa; IL-10); markers of intestinal permeability mediators of inflammation, such as LPS-binding protein (LPB) and zonulin-1.

    Time frame: Baseline

Other outcomes

  1. Change from baseline in fecal microbial taxa quantified by shotgun metagenomics with deep sequencing analysis

    In participating patients a second stool sample with be collected after one year of treatment in order to compare data on microbiota composition with baseline results.

    Time frame: Baseline and 12 months

07

Study locations

2 of 2 sites recruiting
  • Hospital Infantil Universitario Niño Jesús
    Madrid, Madrid 28009, Spain
    Recruiting
  • Institute of Food Science and Technology and Nutrition (ICTAN, CSIC)
    Madrid, Madrid 28040, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Dataset (xls or csv format) with pseudanonymization including: demographic and socioeconomic variables, diagnostic data, blood and fecal biomarkers, body composition parameters, symptoms and psychological test scores. Metagenomic sequencing FASTQ files obtained from human fecal samples

Supporting information: Study protocol

Time frame: Beginning after publication with no end date

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2025
First posted
Jul 15, 2025
StartActual
Aug 29, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Aug 2027
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07066033
Lead sponsor
Esther Nova
Collaborators
Spanish National Research Council (ICTAN, CSIC), FUNDACION PARA LA INVESTIGACIÓN BIOMÉDICA HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESUS
Responsible party
Esther Nova (Principal Investigator, Spanish National Research Council) — Sponsor-investigator
First posted
Jul 15, 2025
Start date
Aug 29, 2024
Primary completion
Dec 2026 (estimated)
Completion
Aug 2027 (estimated)
Last update
Aug 18, 2026

Study contacts

Esther Nova, PhD
Contact
enova@ictan.csic.es
34 5492300 ext. 436322
Esther Nova, PhD
study chair · Spanish National Research Council (CSIC - ICTAN)
Mar Faya, PhD, MD
principal investigator · Hospital Infantil Universitario Niño Jesús

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion